## **Core Concept**
The question tests knowledge on the treatment of leprosy (Hansen's disease) with rifampicin, a key antibiotic used to render patients non-infectious. Leprosy is caused by *Mycobacterium leprae*, and rifampicin is known for its potent bactericidal activity against this organism.

## **Why the Correct Answer is Right**
Rifampicin works by inhibiting RNA synthesis in *Mycobacterium leprae*, leading to a rapid decrease in the bacterial load. Studies have shown that a single dose of rifampicin can significantly reduce the bacterial load, and by extension, the infectivity of the patient. The World Health Organization recommends multidrug therapy (MDT) for leprosy, which includes rifampicin, dapsone, and clofazimine. However, the specific question about becoming non-infective relates to the bactericidal effect of rifampicin. A 3-month course of rifampicin is often cited for its effectiveness in making leprosy patients non-infective.

## **Why Each Wrong Option is Incorrect**
- **Option A:** A few days. This is too short for a multidrug treatment effect and does not accurately reflect the time needed for rifampicin to make a leprosy patient non-infective.
- **Option B:** 3 weeks. While rifampicin starts to act quickly, 3 weeks may not be sufficient to ensure the patient is completely non-infective, given the variability in bacterial load and individual response.
- **Option D:** 6 months. Although some treatment regimens for leprosy may last 6 months or more, the question specifically asks about becoming non-infective with rifampicin, which can occur more rapidly.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that rifampicin is highly effective against *Mycobacterium leprae* and can render a leprosy patient non-infective within a relatively short period, typically cited as 3 months. This is crucial for preventing the spread of leprosy in communities.

## **Correct Answer:** . 3 months.